Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Inclusion Criteria: * Male or female infants aged 6-8 weeks at the time of first vaccination. * Infants with good health, as determined by the medical history, physical examination and clinical judgment of the Investigator. * Informed consent form signed by at least one parent. * Infants born at full term pregnancy (≥ 37 weeks). * Infants with weight-for-length z-score ≥ -2 standard deviation (SD) at the time of enrolment. * Willingness of subjects' parent to comply with the requirements of the protocol. Exclusion Criteria: * History of diphtheria/ tetanus/ pertussis/ hepatitis B/ Haemophilus Influenzae type b/ poliomyelitis infection(s). * Presence of fever ≥ 38°C/ 100.4°F. * Acute illness of moderate to severe intensity according to the clinical judgment of the investigator . * Receipt of antibiotics in the past 3 days * Previous vaccination or planned receipt of any vaccine against diphtheria, tetanus, pertussis, hepatitis B (except birth dose), poliomyelitis (except OPV birth dose) or Haemophilus Influenzae type b infection apart from trial vaccines during the study period. * Administration of any vaccine (except OPV during government immunization campaign) in the 4 weeks preceding the first trial vaccination. * History of major congenital defects or illness that require medical therapy, as determined by medical history or clinical assessment. * History of any clinically significant chronic disease that in the opinion of the Investigator, might interfere with the evaluation of the study objectives. * History of anaphylaxis, or any serious vaccine reaction, or hypersensitivity/allergy to any vaccine or components of study vaccine. * Infants with known or suspected impairment of the immune function, or those receiving immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy or received immunosuppressive therapy prior to study entry * Presence of evolving or changing neurological disorder or infant with a history of seizures and/or encephalopathy. * Known thrombocytopenia or a bleeding disorder. * Known personal or maternal history of HIV, Hepatitis B or Hepatitis C seropositivity. * Planned surgery during the study. * Receipt of blood or blood-derived products or immunoglobulins or planned administration during the trial which might interfere with the assessment of the immune response. * Participation in another clinical trial 4 weeks preceding the trial enrolment or planned participation during the present trial period in another clinical trial. * Infants whose families are planning to leave the area of the study site before the end of the study period.